-
1 Comment
Alliance Pharma plc is currently in a long term uptrend where the price is trading 16.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
Finally, its free cash flow grew by 36.9% to $12M since the same quarter in the previous year.
Based on the above factors, Alliance Pharma plc gets an overall score of 3/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | GB0031030819 |
| CurrencyCode | GBP |
| Exchange | LSE |
| PE Ratio | 0.0 |
|---|---|
| Target Price | 90.71 |
| Beta | 0.57 |
| Dividend Yield | 2.8% |
| Market Cap | 345M |
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for APH.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
